This is a beta version of OpenPrescribing Hospitals for testing and feedback purposes. Data and functionality may be incomplete. Please contact us if you find any issues or have feedback.

Measures

Measures are pre-built analyses of medicines use in hospitals. They provide valuable insights into areas such as cost-effectiveness, patient safety, and adherence to best practices.

Best Value DOACs

Percentage of DOACs that are not rivaroxaban or apixaban tablets.
Tags: Value

Environmentally friendly inhalers

Percentage of inhaler doses that are from metered dose inhalers (MDIs), excluding salbutamol inhalers.
Tags: Greener NHS
🆕

Low value prescribing - co-proxamol

Total indicative cost for co-proxamol tablets and oral suspension
Tags: Safety Value Low value prescribing

Low value prescribing - doxazosin modified release

Percentage of doxazosin modified release of all doxazosin issued.
Tags: Value Low value prescribing
🆕

Low value prescribing - lidocaine plasters

Total lidocaine plasters issued
Tags: Value Low value prescribing

Low value prescribing - perindopril arginine

Percentage of perindopril arginine of all perindopril.
Tags: Value Low value prescribing

Methotrexate tablets

Percentage of methotrexate tablets which are 10mg
Tags: Safety
🆕

SGLT-2 inhibitors

The proportion of sodium-glucose co-transporter 2 (SGLT-2) inhibitors (excluding combination products) not prescribed as dapagliflozin tablets. Combination products are excluded as they do not have specified [Defined Daily Doses (DDDs)](/faq/#what-is-a-defined-daily-dose-ddd) and the quantity of SGLT-2 inhibitors issued as combinations is low. There is a similar measure on [OpenPrescribing](https://openprescribing.net/measure/dapagliflozin/) for primary care, which reports the use of generic dapagliflozin. In OpenPrescribing Hospitals, [branded and generic products cannot be distinguished](https://www.bennett.ox.ac.uk/blog/2025/07/you-asked-can-we-monitor-the-usage-of-biosimilars-in-secondary-care-using-openprescribing-hospitals/). For this reason, we report dapagliflozin use as a proportion of all SGLT-2 inhibitor use.
Tags: Low value prescribing
🆕

Uptake of atezolizumab subcutaneous

The percentage of atezolizumab that is issued as the subcutaneous formulation.
Tags: Efficiency
🆕

Uptake of nivolumab subcutaneous

The percentage of nivolumab that is issued as the subcutaneous formulation.
Tags: Efficiency

Uptake of Phesgo®

The percentage of pertuzumab that is issued as the combined preparation, Phesgo®.
Tags: Efficiency